APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Vigilance and proactivity are critical in reducing the burden of disease
Document ID: PC-MY-102711
20/09/2022
Author: Boehringer Ingelheim
Interstitial lung disease is the leading cause of mortality in SSc and occurs within 3 years of SSc diagnosis.1-3 Early and regular screening is essential to detect SSc-ILD at its outset.4
References:
1. Steen VD, et al. Ann Rheum Dis. 2007;66(7):940-944.
2. Tyndall AJ, et al. Ann Rheum Dis. 2010;69(10):1809-1815.
3. Solomon JJ, et al. Eur Respir Rev. 2013;22(127):6-19.
4. Chowaniec M, et al. Reumatologia. 2018;56(4):249-254.
RELATED CONTENT
PC-MY-102711
Production date: September 2022
Production date: September 2022